Literature DB >> 33623089

Quantifying cell death induced by doxorubicin, hyperthermia or HIFU ablation with flow cytometry.

Paul Christopher Lyon1,2, Visa Suomi3, Philip Jakeman4, Leticia Campo4, Constantin Coussios3, Robert Carlisle3.   

Abstract

Triggered release and targeted drug delivery of potent anti-cancer agents using hyperthermia-mediated focused-ultrasound (FUS) is gaining momentum in the clinical setting. In early phase studies, tissue biopsy samples may be harvested to assess drug delivery efficacy and demonstrate lack of instantaneous cell death due to FUS exposure. We present an optimised tissue cell recovery method and a cell viability assay, compatible with intra-cellular doxorubicin. Flow cytometry was used to determine levels of cell death with suspensions comprised of: (i) HT29 cell line exposed to hyperthermia (30 min at 47 °C) and/or doxorubicin, or ex-vivo bovine liver tissue exposed to (ii) hyperthermia (up to 2 h at 45 °C), or (iii) ablative high intensity FUS (HIFU). Flow cytometric analysis revealed maximal cell death in HT29 receiving both heat and doxorubicin insults and increases in both cell granularity (p < 0.01) and cell death (p < 0.01) in cells recovered from ex-vivo liver tissue exposed to hyperthermia and high pressures of HIFU (8.2 MPa peak-to-peak free-field at 1 MHz) relative to controls. Ex-vivo results were validated with microscopy using pan-cytokeratin stain. This rapid, sensitive and highly quantitative cell-viability method is applicable to the small masses of liver tissue typically recovered from a standard core biopsy (5-20 mg) and may be applied to tissues of other histological origins including immunostaining.

Entities:  

Year:  2021        PMID: 33623089     DOI: 10.1038/s41598-021-83845-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  69 in total

1.  Rational for clinical application of hyperthermia and drugs.

Authors:  R Engelhardt
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  1987 Apr-Jun

Review 2.  High-intensity focused ultrasound in the treatment of solid tumours.

Authors:  James E Kennedy
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 3.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.

Authors:  D Needham; M W Dewhirst
Journal:  Adv Drug Deliv Rev       Date:  2001-12-31       Impact factor: 15.470

4.  A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.

Authors:  D Needham; G Anyarambhatla; G Kong; M W Dewhirst
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 5.  Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.

Authors:  Ronnie T P Poon; Nicholas Borys
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

6.  Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.

Authors:  Michael D Gray; Paul C Lyon; Christophoros Mannaris; Lisa K Folkes; Michael Stratford; Leticia Campo; Daniel Y F Chung; Shaun Scott; Mark Anderson; Robert Goldin; Robert Carlisle; Feng Wu; Mark R Middleton; Fergus V Gleeson; Constantin C Coussios
Journal:  Radiology       Date:  2019-01-15       Impact factor: 11.105

Review 7.  Possible benefits of hyperthermia to chemotherapy.

Authors:  C D Kowal; J R Bertino
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

8.  Hyperthermia adds to chemotherapy.

Authors:  Rolf D Issels
Journal:  Eur J Cancer       Date:  2008-09-11       Impact factor: 9.162

9.  Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.

Authors:  Paul C Lyon; Lucy F Griffiths; Jenni Lee; Daniel Chung; Robert Carlisle; Feng Wu; Mark R Middleton; Fergus V Gleeson; Constantin C Coussios
Journal:  J Ther Ultrasound       Date:  2017-11-02

10.  Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

Authors:  Paul C Lyon; Michael D Gray; Christophoros Mannaris; Lisa K Folkes; Michael Stratford; Leticia Campo; Daniel Y F Chung; Shaun Scott; Mark Anderson; Robert Goldin; Robert Carlisle; Feng Wu; Mark R Middleton; Fergus V Gleeson; Constantin C Coussios
Journal:  Lancet Oncol       Date:  2018-07-11       Impact factor: 41.316

View more
  1 in total

Review 1.  The Employment of Genera Vaccinium, Citrus, Olea, and Cynara Polyphenols for the Reduction of Selected Anti-Cancer Drug Side Effects.

Authors:  Jessica Maiuolo; Vincenzo Musolino; Micaela Gliozzi; Cristina Carresi; Francesca Oppedisano; Saverio Nucera; Federica Scarano; Miriam Scicchitano; Lorenza Guarnieri; Francesca Bosco; Roberta Macrì; Stefano Ruga; Antonio Cardamone; Anna Rita Coppoletta; Sara Ilari; Annachiara Mollace; Carolina Muscoli; Francesco Cognetti; Vincenzo Mollace
Journal:  Nutrients       Date:  2022-04-10       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.